The stock is listed on the Nasdaq Global Market

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a public offering by Nurix Therapeutics, Inc. of 11,916,667 shares of common stock at $15.00 per share and pre-funded warrants to purchase 1,500,100 shares of common stock at $14.999 per pre-funded warrant, which included 1,750,000 shares of common stock from the full exercise of the underwriters’ option to purchase additional shares, for total gross proceeds of approximately $175.0 million. The common stock is listed on the Nasdaq Global Market under the symbol “NRIX.”

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions and other challenging diseases.

The Davis Polk corporate team included partner Emily Roberts and associates Jonathan Bye and Ivey Eugene. The tax team included partner Mario J. Verdolini and associate Tyler Scheiner. The intellectual property team included partner David R. Bauer and associates Adrian Rabin and Jay Krishnan. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post